{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T16:48:16Z","timestamp":1795020496847,"version":"4.10.1"},"reference-count":135,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["K142273"],"award-info":[{"award-number":["K142273"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TKP2021-EGA","award":["TKP2021-EGA-18"],"award-info":[{"award-number":["TKP2021-EGA-18"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Novel antidiabetic drugs introduced in the last decade have not only revolutionized the treatment of type 2 diabetes mellitus but have also changed our cardiovascular risk reduction strategy. Glucagon-like peptide-1 (GLP-1) receptor agonists reduce the risk of atherosclerotic diseases primarily through their complex anti-atherosclerotic effect due to their endothelial function-improving, anti-inflammatory, anti-thrombotic, and plaque-stabilizing effects. Sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors, on the other hand, have a favorable cardiovascular effect, mainly by increasing sodium excretion, reducing plasma volume, enhancing the use of ketone bodies as metabolic substrates in heart and kidney tissues, and reducing oxidative stress and uric acid serum levels. However, when using these two groups of drugs, important questions arise. What criteria should be used to decide on the administration of one or the other class of drugs? Which group of agents can be used more effectively to reduce our patients\u2019 cardiovascular risk? What are the possible adverse effects? What can be gained by combining the two drugs? Our objective was to provide a current literature-based and comparative summary on the mechanisms of action, cardiovascular-risk-reducing efficacy, and safety profiles of these two drug classes, with an emphasis on identifying key factors influencing everyday clinical decision-making.<\/jats:p>","DOI":"10.3390\/biomedicines13112595","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:47:36Z","timestamp":1761266856000},"page":"2595","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Complementary Yet Distinct Roles of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Cardiovascular Risk Reduction"],"prefix":"10.3390","volume":"13","author":[{"given":"N\u00f3ra","family":"Homor\u00f3di","sequence":"first","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"Varga","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Hematology, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1922-2052","authenticated-orcid":false,"given":"Zolt\u00e1n","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc","family":"Sztanek","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9761-9595","authenticated-orcid":false,"given":"Mariann","family":"Harangi","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Institute of Health Studies, Faculty of Health Sciences, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"ELKH-UD Vascular Pathophysiology Research Group 11003, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/eurjpc\/zwae281","article-title":"Global burden of cardiovascular diseases: Projections from 2025 to 2050","volume":"32","author":"Chong","year":"2025","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","article-title":"Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality","volume":"389","author":"Magnussen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Dhindsa, D.S., Sandesara, P.B., Shapiro, M.D., and Wong, N.D. (2020). The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. Front. Cardiovasc. Med., 7.","DOI":"10.3389\/fcvm.2020.00088"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s40265-024-02090-9","article-title":"GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy","volume":"84","author":"Scheen","year":"2024","journal-title":"Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Gajjar, A., Raju, A.K., Menon, M., Shah, S.A.Y., Dani, S., and Weinberg, A. (2025). SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular-Kidney-Metabolic Syndrome. Biomedicines, 13.","DOI":"10.3390\/biomedicines13081924"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"Collaborators","year":"2023","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: An updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2025). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025. Diabetes Care, 48, S181\u2013S206.","DOI":"10.2337\/dc25-S009"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI112855","article-title":"Insulinotropin: Glucagon-like peptide I (7\u201337) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas","volume":"79","author":"Mojsov","year":"1987","journal-title":"J. Clin. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0014-5793(87)81430-8","article-title":"Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut","volume":"211","author":"Holst","year":"1987","journal-title":"FEBS Lett."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI990","article-title":"Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans","volume":"101","author":"Flint","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ajcnut.2024.01.007","article-title":"Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions\u2014A narrative review","volume":"119","author":"Huber","year":"2024","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3945\/jn.111.139824","article-title":"Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients","volume":"141","author":"Wong","year":"2011","journal-title":"J. Nutr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1210\/endo.133.1.8319572","article-title":"Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop","volume":"133","author":"Roberge","year":"1993","journal-title":"Endocrinology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1210\/endo.137.6.8641190","article-title":"Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut","volume":"137","author":"Roberge","year":"1996","journal-title":"Endocrinology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014State-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1111\/dom.15058","article-title":"Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial","volume":"25","author":"McGuire","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of Oral Semaglutide Compared with Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients with Type 2 Diabetes: A Randomized Clinical Trial","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Sztanek, F., T\u00f3th, L.I., Pet\u0151, A., Herny\u00e1k, M., Di\u00f3szegi, \u00c1., and Harangi, M. (2024). New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes-Beyond and within GLP-1 Receptor Agonists. Biomedicines, 12.","DOI":"10.3390\/biomedicines12061320"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/ki.2009.87","article-title":"Renal sodium-glucose transport: Role in diabetes mellitus and potential clinical implications","volume":"75","author":"Bakris","year":"2009","journal-title":"Kidney Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","article-title":"SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 Protein Inhibition Decreases Renal Lipid Accumulation, Inflammation, and the Development of Nephropathy in Diabetic Mice","volume":"292","author":"Wang","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","article-title":"Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia","volume":"306","author":"Rieg","year":"2014","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Xu, J., Hirai, T., Koya, D., and Kitada, M. (2021). Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches. J. Clin. Med., 11.","DOI":"10.3390\/jcm11010137"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Dai, Z.C., Chen, J.X., Zou, R., Liang, X.B., Tang, J.X., and Yao, C.W. (2023). Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1213473"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12933-023-01855-y","article-title":"Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: A narrative review","volume":"22","author":"Panico","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bph.15462","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor","volume":"179","author":"Keppeler","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/db13-1440","article-title":"Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model","volume":"63","author":"Richards","year":"2014","journal-title":"Diabetes"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.tcm.2024.03.003","article-title":"The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action","volume":"34","author":"Alexiadou","year":"2024","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCRESAHA.117.312136","article-title":"Endocardial Cell Plasticity in Cardiac Development, Diseases and Regeneration","volume":"122","author":"Zhang","year":"2018","journal-title":"Circ. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: Cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"101895","DOI":"10.1016\/j.toxrep.2025.101895","article-title":"Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential","volume":"14","author":"Abdelhamid","year":"2025","journal-title":"Toxicol. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","article-title":"GLP-1 receptor agonists and atherosclerosis protection: The vascular endothelium takes center stage","volume":"326","author":"Park","year":"2024","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Skrobucha, A., Pindlowski, P., Krajewska, N., Grabowski, M., and Jonik, S. (2024). Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: A comprehensive review. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1446468"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"H1361","DOI":"10.1152\/ajpheart.00885.2010","article-title":"Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes","volume":"300","author":"Ravassa","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE\u2212\/\u2212 and LDLr\u2212\/\u2212 Mice by a Mechanism That Includes Inflammatory Pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic. Transl. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2337\/db14-1577","article-title":"GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R","volume":"64","author":"Yusta","year":"2015","journal-title":"Diabetes"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e0203223","DOI":"10.1128\/mbio.02032-23","article-title":"Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases","volume":"15","author":"Zeng","year":"2024","journal-title":"mBio"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.cmet.2022.08.003","article-title":"Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation","volume":"34","author":"Wong","year":"2022","journal-title":"Cell Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s42000-018-0014-8","article-title":"Diabetes and lipid metabolism","volume":"17","author":"Athyros","year":"2018","journal-title":"Hormones"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11886-021-01455-w","article-title":"Mechanisms and Treatment of Dyslipidemia in Diabetes","volume":"23","author":"Bahiru","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1515\/mr-2024-0011","article-title":"Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism","volume":"4","author":"Hoffman","year":"2024","journal-title":"Med. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/ATVBAHA.117.310251","article-title":"GLP-1 Elicits an Intrinsic Gut-Liver Metabolic Signal to Ameliorate Diet-Induced VLDL Overproduction and Insulin Resistance","volume":"37","author":"Khound","year":"2017","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1161\/ATVBAHA.114.304873","article-title":"Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain-Gut Axis","volume":"35","author":"Farr","year":"2015","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12933-018-0689-9","article-title":"Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db\/db mice through a HNF-1a dependent mechanism","volume":"17","author":"Yang","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"101590","DOI":"10.1016\/j.molmet.2022.101590","article-title":"GLP-1 attenuates intestinal fat absorption and chylomicron production via vagal afferent nerves originating in the portal vein","volume":"65","author":"Hoffman","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: Systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"T\u00f3th, L.I., Hars\u00e1nyi, A., Csiha, S., Moln\u00e1r, \u00c1., L\u0151rincz, H., Nagy, A.C., Paragh, G., Harangi, M., and Sztanek, F. (2025). Semaglutide Improves Lipid Subfraction Profiles in Type 2 Diabetes: Insights from a One-Year Follow-Up Study. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26135951"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation","volume":"138","author":"Moiz","year":"2025","journal-title":"Am. J. Med."},{"key":"ref_60","first-page":"T1","article-title":"Effects of glucagon-like peptide 1 on appetite and body weight: Focus on the CNS","volume":"221","author":"Ijzerman","year":"2014","journal-title":"J. Endocrinol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3945\/jn.114.206029","article-title":"Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling","volume":"145","author":"Ronveaux","year":"2015","journal-title":"J. Nutr."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11481-024-10142-w","article-title":"Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis","volume":"19","author":"Peixoto","year":"2024","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1530\/JOE-18-0374","article-title":"The key role of a glucagon-like peptide-1 receptor agonist in body fat redistribution","volume":"240","author":"Zhao","year":"2019","journal-title":"J. Endocrinol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2337\/dc19-2251","article-title":"Cardiovascular Risk Reduction with Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/eurheartj\/ehab765","article-title":"SGLT2 inhibitors: The statins of the 21st century","volume":"43","author":"Braunwald","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0006-3002(62)90543-7","article-title":"Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine, in vitro","volume":"56","author":"Alvarado","year":"1962","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.amjmed.2023.04.019","article-title":"Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure","volume":"137","author":"Greene","year":"2024","journal-title":"Am. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/obr.12841","article-title":"Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities","volume":"20","author":"Brown","year":"2019","journal-title":"Obes. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/obr.12755","article-title":"Weight loss associated with sodium-glucose cotransporter-2 inhibition: A review of evidence and underlying mechanisms","volume":"19","author":"Lee","year":"2018","journal-title":"Obes. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e09","DOI":"10.15420\/cfr.2023.25","article-title":"Haemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitor Treatment in Chronic Heart Failure Patients","volume":"10","author":"Nilsson","year":"2024","journal-title":"Card. Fail. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11906-022-01170-z","article-title":"Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition","volume":"24","author":"Herat","year":"2022","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e007197","DOI":"10.1161\/CIRCHEARTFAILURE.120.007197","article-title":"Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors","volume":"13","author":"Packer","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: Inhibition of Na","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"105068","DOI":"10.1016\/j.phrs.2020.105068","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials","volume":"160","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Yahaya, J.J., Doya, I.F., Morgan, E.D., Ngaiza, A.I., and Bintabara, D. (2023). Poor glycemic control and associated factors among patients with type 2 diabetes mellitus: A cross-sectional study. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-36675-3"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-135-9-200111060-00012","article-title":"Clinical inertia","volume":"135","author":"Phillips","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/dom.13088","article-title":"Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review","volume":"20","author":"Khunti","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.2337\/dc18-0116","article-title":"Clinical Inertia in Type 2 Diabetes Management: Evidence From a Large, Real-World Data Set","volume":"41","author":"Pantalone","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.2337\/dc16-0227","article-title":"Intensification of Diabetes Therapy and Time Until A1C Goal Attainment Among Patients with Newly Diagnosed Type 2 Diabetes Who Fail Metformin Monotherapy Within a Large Integrated Health System","volume":"39","author":"Pantalone","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.2011.490","article-title":"Clinical inertia as a clinical safeguard","volume":"305","author":"Giugliano","year":"2011","journal-title":"JAMA"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"569","DOI":"10.7326\/M17-0939","article-title":"Hemoglobin A1c Targets for Glycemic Control with Pharmacologic Therapy for Nonpregnant Adults with Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians","volume":"168","author":"Qaseem","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40618-018-0951-8","article-title":"Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes","volume":"42","author":"Giugliano","year":"2019","journal-title":"J. Endocrinol. Investig."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13098-024-01334-8","article-title":"Trends and regional differences in antidiabetic medication use: A nationwide retrospective observational study","volume":"16","author":"Csatordai","year":"2024","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/HCO.0000000000000892","article-title":"Permission to prescribe: Do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?","volume":"36","author":"Sharma","year":"2021","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","article-title":"Cardiovascular, Kidney, and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"150","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e2317886","DOI":"10.1001\/jamanetworkopen.2023.17886","article-title":"Evaluation of Out-of-Pocket Costs and Treatment Intensification with an SGLT2 Inhibitor or GLP-1 RA in Patients with Type 2 Diabetes and Cardiovascular Disease","volume":"6","author":"Luo","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Caturano, A., Galiero, R., Rocco, M., Tagliaferri, G., Piacevole, A., Nilo, D., Di Lorenzo, G., Sardu, C., Vetrano, E., and Monda, M. (2024). Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care. Biomedicines, 12.","DOI":"10.3390\/biomedicines12092039"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"109855","DOI":"10.1016\/j.diabres.2022.109855","article-title":"Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes","volume":"187","author":"Luo","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.2337\/dc24-1082","article-title":"Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration-A Danish Cohort Study","volume":"47","author":"Ladebo","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: A systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamapsychiatry.2025.0091","article-title":"Suicide and Self-Harm Events with GLP-1 Receptor Agonists in Adults with Diabetes or Obesity: A Systematic Review and Meta-Analysis","volume":"82","author":"Ebrahimi","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","article-title":"Gastrointestinal effects of GLP-1 receptor agonists: Mechanisms, management, and future directions","volume":"9","author":"Jalleh","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse Effects of GLP-1 Receptor Agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev. Diabet. Stud."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1517\/14656566.2015.1052740","article-title":"Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice","volume":"16","author":"Artigas","year":"2015","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2337\/cd18-0034","article-title":"Oral Semaglutide","volume":"36","author":"Bui","year":"2018","journal-title":"Clin. Diabetes"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/14740338.2024.2354885","article-title":"Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile","volume":"23","author":"Scheen","year":"2024","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.7326\/M21-2941","article-title":"First-Line Therapy for Type 2 Diabetes with Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: A Cost-Effectiveness Study","volume":"175","author":"Choi","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.pcd.2024.06.002","article-title":"Knowledge and prescribing behaviour of Flemish general practitioners regarding novel glucose-lowering medications: Online cross-sectional survey","volume":"18","author":"Lecomte","year":"2024","journal-title":"Prim. Care Diabetes"},{"key":"ref_104","first-page":"34","article-title":"Medicare formulary restrictions for glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors used in type 2 diabetes mellitus: 2019\u20132023","volume":"30","author":"Wisniewski","year":"2024","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11892-024-01537-3","article-title":"Diabetes, SGLT-2 Inhibitors, and Urinary Tract Infection: A Review","volume":"24","author":"Pishdad","year":"2024","journal-title":"Curr. Diabetes Rep."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"102664","DOI":"10.1016\/j.cpcardiol.2024.102664","article-title":"Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials","volume":"49","author":"Bhanushali","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/a-2347-9824","article-title":"Genito Urinary Infection and Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Receiving SGLT2 Inhibitors: Evidence from a Systematic Literature Review of Landmark Randomized Clinical Trial","volume":"74","author":"Arshad","year":"2024","journal-title":"Drug Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e003666","DOI":"10.1136\/bmjdrc-2023-003666","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"Chow","year":"2023","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"102275","DOI":"10.1016\/j.dsx.2021.102275","article-title":"Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period","volume":"15","author":"Menghoum","year":"2021","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S2213-8587(22)00387-4","article-title":"Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): A multicentre, randomised, double-blind, parallel group, phase 3 trial","volume":"11","author":"Laffel","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/dom.14887","article-title":"Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study","volume":"25","author":"Humphreys","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"102661","DOI":"10.1016\/j.dsx.2022.102661","article-title":"Cardiorenal disease management in type 2 diabetes: An expert consensus","volume":"16","author":"Mohan","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/dom.12982","article-title":"Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor","volume":"19","author":"DeFronzo","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/dom.16077","article-title":"Early combination therapy with SGLT2i and GLP-1 RA or dual GIP\/GLP-1 RA in type 2 diabetes","volume":"27","author":"Vale","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2337\/dc18-0680","article-title":"Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial","volume":"41","author":"Jabbour","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/dom.13206","article-title":"Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study","volume":"20","author":"Jabbour","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.2337\/dc19-1350","article-title":"Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial","volume":"43","author":"Jabbour","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): A 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): A randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Li, C., Luo, J., Jiang, M., and Wang, K. (2022). The Efficacy and Safety of the Combination Therapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.838277"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/dom.14108","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis","volume":"22","author":"Mantsiou","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12020-019-02175-6","article-title":"The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: A systematic review and meta-analysis","volume":"67","author":"Guo","year":"2020","journal-title":"Endocrine"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1111\/dom.13267","article-title":"Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study","volume":"20","author":"Harashima","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s13300-018-0455-8","article-title":"Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study","volume":"9","author":"Ishihara","year":"2018","journal-title":"Diabetes Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/dom.13978","article-title":"Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial","volume":"22","author":"Blonde","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jacc.2023.05.048","article-title":"GLP-1 Receptor Agonist Therapy with and Without SGLT2 Inhibitors in Patients with Type 2 Diabetes","volume":"82","author":"Neves","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-019-0942-x","article-title":"Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: Insights from the EXSCEL trial","volume":"18","author":"Clegg","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: A SMART-C collaborative meta-analysis of randomised controlled trials","volume":"12","author":"Apperloo","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_129","first-page":"e078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: Population based cohort study","volume":"385","author":"Treves","year":"2024","journal-title":"BMJ"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e70108","DOI":"10.1111\/1753-0407.70108","article-title":"Trends in Pharmacological Treatment of Patients with New Onset Type 2 Diabetes: Usage Patterns in an Evolving Guideline Landscape","volume":"17","author":"Hou","year":"2025","journal-title":"J. Diabetes"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/eurjpc\/zwac315","article-title":"Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA\/EASD consensus report in a national population of patients with type 2 diabetes","volume":"30","author":"Lim","year":"2023","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e70057","DOI":"10.1002\/dmrr.70057","article-title":"Recommendations for the Management of Diabetes During Ramadan Applying the Principles of the ADA\/ EASD Consensus: Update 2025","volume":"41","author":"Ibrahim","year":"2025","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12933-024-02180-8","article-title":"CVOT Summit Report 2023: New cardiovascular, kidney, and metabolic outcomes","volume":"23","author":"Schnell","year":"2024","journal-title":"Cardiovasc. Diabetol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/11\/2595\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T04:19:29Z","timestamp":1761365969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/11\/2595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":135,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["biomedicines13112595"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13112595","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}